… We report the results of a multi-institutional phase II trial that used preoperative full-dose
gemcitabine and radiotherapy for patients with potentially resectable pancreatic carcinoma. …

… evaluate preoperative treatment with full-dose gemcitabine, … that have used full-dose
gemcitabine with conformal radiation … tumor to concurrent radiation.12-15 This is in contrast to …

… phase II trial was to evaluate the safety and efficacy of a modified version of this novel
chemoradiotherapy regimen delivered in a multi-institutional … During the preoperative phase of …

… and a follow-up multi-institutional Phase II trial confirmed this … We hypothesized that (1)
concurrent full-dose gemcitabine, a … excess marginal failures; and (2) the introduction of more …

… We and others have achieved encouraging survival rates using preoperative gemcitabine-based
chemoradiotherapy for patients with potentially resectable PDAC. However, other …

… However, a phase II trial of this novel gemcitabine-based chemoradiotherapy approach, at
a … Therapy Oncology Group trial found no survival advantage in a multi-institutional setting. …

… a multi-institutional experience using full-dose gemcitabine … of this phase I trial, a multi-institutional
phase II trial limited to … , et al: A phase I study of preoperative gemcitabine (GEM) with …

… Background: We report the results of a multi-institutional phase II trial that used preoperative
full-dose gemcitabine and radiotherapy for patients with potentially resectable pancreatic …

… phase II dose for GEM and CDDP in combination with full-dose radiotherapy (5040 cGy) is
300 mg/m 2 … Table 7 summarizes the pathologic and perioperative morbidities and survival. …

… directed at the preoperative tumor volume … gemcitabine-based chemoradiotherapy regimen
to have been investigated in the adjuvant setting. An ongoing multi-institutional Phase II trial …